Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.
Suresh S. Ramalingam
Consultant or Advisory Role - Synta (U)
Bojan Zaric
Consultant or Advisory Role - Synta (U)
Honoraria - Synta
Research Funding - Synta
Timur Ceric
No relevant relationships to disclose
Tudor E. Ciuleanu
No relevant relationships to disclose
James F. Spicer
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Dmitry Komov
No relevant relationships to disclose
Enriqueta Felip
No relevant relationships to disclose
Enric Carcereny
No relevant relationships to disclose
Joachim Von Pawel
Consultant or Advisory Role - Daiichi Sankyo (U); Pfizer (U); Vertex (U)
Miroslav Samarzija
No relevant relationships to disclose
Thierry Pieters
No relevant relationships to disclose
Michael Schenker
Research Funding - Synta
Manuel R. Modiano
Research Funding - Arizona Clinical Research
Rodryg Ramlau
No relevant relationships to disclose
Marianna Koczywas
No relevant relationships to disclose
Florentina Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
Ilker Yalcin
Employment or Leadership Position - Synta
Stock Ownership - Synta
Vojislav M. Vukovic
Employment or Leadership Position - Synta
Stock Ownership - Synta
Dean Fennell
Consultant or Advisory Role - Synta (U)
Honoraria - Synta
Research Funding - Synta
Other Remuneration - Synta